Anti-LYAR polyclonal antibody

We present high dispersion HST GHRS UV spectroscopic observations of 8 HII galaxies covering a wide range of metallicities and physical properties. We have found Lyar emission in 4 galaxies with blueshifted absorption features, leading to P Cygni like profiles in 3 of them. In all these objects the O I and Si II absorption lines are also blueshifted with respect to the ionized gas, indicating that the neutral gas is outflowing in these galaxies with velocities up to 200 km s(-1) or more. The rest of the sample shows broad damped Ly alpha absorption profiles centered at the wavelength corresponding to the redshift of the H II emitting gas. We therefore find that the velocity structure of the neutral gas in these galaxies is the driving factor that determines the detectability of Ly alpha in emission. Relatively small column densities of neutral gas with even very small dust content would destroy the Ly alpha emission if this gas is static with respect to the ionized region where Ly alpha photons originate. The situation changes dramatically when most of the neutral gas is velocity-shifted with respect to the ionized regions because resonant scattering by neutral hydrogen will be most efficient at wavelengths shorter than the Ly alpha emission, allowing the Ly alpha photons to escape (at least partially). This mechanism complements the effect of porosity in the neutral interstellar medium discussed by other authors, which allows to explain the escape of Ly alpha photons in regions surrounded by static neutral gas, but with only partial covering factors. The anisotropy of these gas flows and their dependence on the intrinsic properties of the violent star-forming episodes taking place in these objects (age, strength, gas geometry,...) might explain (in part) the apparent lack of correlation between other properties (like metallicity) and the frequency of occurence and strength of Ly alpha emission in star-forming galaxies. Attempts to derive the comoving star-formation rate at high redshifts from Ly alpha emission searches are highly questionable.

Ovarian cancer patients with different tumor stages and cell differentiation might be distinguished from each other by gene expression profiles in whole blood cell mRNA by the Affymetrix Human Gene 1.0 ST Array. We also examined if there is any association with other clinical variables, response to therapy, and residual tumor burden after surgery. Patients were divided into two groups, one with poor prognosis, advanced stage and poorly differentiated tumors (n = 22), and one group with good prognosis, early stage and well-to medium differentiated tumors (n = 11). Six genes were found to be differentially expressed: the PDIA3, LYAR, NOP14, NCALD and MTSS1 genes were down-regulated and the CYP1B1 gene expression was up-regulated in the poor prognosis group, all with p value <0.05, adjusted for mass comparison. In survival analyses, CYP1B1, MTSS1, NCALD and NOP14 remained significantly different (p<0.05). Patient groups did not differ in any transcript related to acute phase or immune responses. This minimal gene expression signature of prognostic ovarian cancer-related genes opens up an avenue for more practicable monitoring of ovarian cancer patients by simple peripheral blood tests, which may evolve into a tool to guide selection of curative and postoperative supportive therapies.